ARTICLE | Preclinical News
CYLD expression could slow progression of NASH
January 3, 2018 1:00 AM UTC
In a paper published in Nature Medicine, researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in animal models.
Deubiquitinating enzymes (DUBs) remove polyubiquitin chains from proteins, preventing their degradation by the proteasome. Based on their ability to control protein levels, DUBs are emerging as a promising class of targets in a variety of diseases (see BioCentury Innovations, Nov. 2, 2017)...